A phase I study of daily everolimus plus low-dose weekly cisplatin for patients with advanced solid tumors
Antineoplastic Combined Chemotherapy Protocols
The phase II recommended dose is everolimus 10 mg/day (days 1-21) + cisplatin 20 mg/m(2) (days 1, 8, and 15) of a 28-day cycle. PK data demonstrate dose-proportional increases in exposure, as previously described for everolimus monotherapy. Anti-tumor activity was observed in several tumor types.